Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2009

Sandoz’ Biosimilar to Amgen’s Anemia Drug Gets EU Go-Ahead

  • Sandoz received the green light to market its biosimilar to Amgen’s neutropenia treatment, Neupogen®, from the European Commission. While the U.S. drags it feet in creating a path for follow-on biologic approval, the decision on Sandoz’ filgrastim marks the firm’s third EC sanction.
    The Sandoz product is approved for the same range of indications as Neupogen and offers patients comparable quality, safety, and efficacy combined with greater cost-effectiveness. Sandoz also points out that its filgrastim needlestick protection device decreases the risks of injury and exposure to blood-born infection.
    Sandoz won approval for the first biosimilar in the EU in April 2006, when its human growth hormone, Omnitrope®, was given the go-ahead. Erythropoetin Binocrit® and glycoprotein Epoetin followed suit in August 2007.
    Teva Pharmaceutical already has a version of Neupogen on the market in the EU. The drug was developed with Ratiopharm.



    To comment on this story, go to BLOGbiotech.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »